Basic Information
| LncRNA/CircRNA Name | CASC9 |
| Synonyms | NA |
| Region | GRCh38_8:75223404-75324741 |
| Ensemble | ENSG00000249395 |
| Refseq | NR_103848 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hemangioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, etc. |
| Sample | involuting-phase HA tumor tissues, and proliferating-phase HA tumor tissues, HA-derived endothelial cell (HDECs) |
| Expression Pattern | up-regulated |
| Function Description | The expression of CASC9 was significantly elevated in HA tissue compared to normal tissue. Down-regulation of CASC9 inhibited proliferation, migration, and invasion of HDECs. The translation of cyclinD1, N-cadherin, Twist, and MMP2 was also decreased by CASC9 knockdown treatment. Furthermore, CASC9 over-expression exerted the opposite effect of proliferation, migration, and invasion of HDECs. We also found that CASC9 interacts with miR- 125a-3p/Nrg1 to regulate cellular functions. Interestingly, miR-125a-3p can reverse the effect of CASC9 on proliferation, migration, and invasion of HDECs. Together, the clinical data showed that CASC9 expression is negatively correlated with miR-125a-3p expression and positively correlated with Nrg1 expression. CASC9 also exerted anti-tumorigenesis capability in vivo. |
| Pubmed ID | 30662268 |
| Year | 2019 |
| Title | lncRNA CASC9 regulates cell migration and invasion in hemangioma endothelial cells by targeting miR-125a-3p/Nrg1 |
External Links
| Links for CASC9 | GenBank HGNC NONCODE |
| Links for hemangioma | OMIM COSMIC |